A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)

2022-503114-23-00 Protocol STML-ELA-0222 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 19 Dec 2023 · Status Ongoing, recruiting · 8 EU/EEA countries · 48 sites · Protocol STML-ELA-0222

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 640
Countries 8
Sites 48

Breast Cancer

Key facts

Sponsor
Stemline Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
19 Dec 2023 → ongoing
Decision date (initial)
2023-10-23
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-503114-23-00
WHO UTN
U1111-1286-9637
ClinicalTrials.gov
NCT05386108

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Breast Cancer

VersionLevelCodeTermSystem organ class
20.0 LLT 10027475 Metastatic breast cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Stemline Therapeutics Inc.

Sponsor organisation
Stemline Therapeutics Inc.
Address
750 Lexington Avenue
City
New York
Postcode
10022-1200
Country
United States

Scientific contact point

Organisation
Stemline Therapeutics Inc.
Contact name
Carlos A. Garay, MD

Public contact point

Organisation
Stemline Therapeutics Inc.
Contact name
Carlos A. Garay, MD

Locations

8 EU/EEA countries · 48 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 40 5
Czechia Ended 40 2
France Ongoing, recruiting 40 5
Germany Ended 40 7
Hungary Ended 40 2
Italy Ongoing, recruiting 40 8
Poland Ended 40 5
Spain Ongoing, recruiting 40 14
Rest of world
Turkey, United States, Argentina, Brazil, Australia, Korea, Republic of, United Kingdom, Israel
320

Investigational sites

Belgium

5 sites · Ongoing, recruiting
UZ Leuven
Gynaecological Oncology, Herestraat 49, 3000, Leuven
Institut Jules Bordet
Clinical Trials Conduct Unit, Mijlenmeersstraat 90, 1070, Brussels
Vitaz
Oncology, Moerlandstraat 1, 9100, Sint-Niklaas
Grand Hopital De Charleroi
Oncology and Hematology, Rue Du Campus Des Viviers 1, 6060, Charleroi
Hopital De Libramont
Oncology, Avenue De Houffalize 35, 6800, Libramont-Chevigny

Czechia

2 sites · Ended
University Hospital Olomouc
Onkologická klinika, Zdravotniku 248/7, 779 00, Olomouc
Onkologická ambulance Nemocnice Hořovice - Multiscan s.r.o.
Onkologie, K Nemocnici 1106/14, 268 01, Hořovice

France

5 sites · Ongoing, recruiting
Centre Hospitalier Lyon Sud
Medical Oncology, 165 Chemin Du Grand Revoyet, 69310, Pierre-Benite
Oncopole Claudius Regaud
Medical Oncology, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Centre De Cancerologie Du Grand Montpellier
Medical Oncology, 25 Rue De Clementville, 34070, Montpellier
Institut Gustave Roussy
Medical Oncology and Hematology, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Henri Becquerel
Medical Oncology, 1 Rue D Amiens, 76000, Rouen

Germany

7 sites · Ended
Marienhospital Bottrop gGmbH
Gynäkologie, Josef-Albers-Strasse 70, Sued-West-Innenstadt, Bottrop
Universitaetsklinikum Tuebingen AöR
Department für Frauengesundheit, Calwerstrasse 7, Innenstadt, Tuebingen
Universitaetsklinikum Mannheim GmbH
Gynäkologie/ Onkologie, Theodor-Kutzer-Ufer 1-3, Wohlgelegen, Mannheim
Technische Universitat Dresden
Medizinische Fakultät Carl Gustav Carus; Gynäkologisches Krebszentrum, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Klinikum Kassel GmbH
Klinik für Frauenheilkunde und Geburtshilfe, Moenchebergstrasse 41-43, Fasanenhof, Kassel
Klinikum rechts der Isar der TU Muenchen AöR
Frauenklinik, Ismaninger Strasse 22, Au-Haidhausen, Munich
KEM I Evang. Kliniken Essen-Mitte gGmbH
Senologie/ Brustzentrum, Henricistrasse 92, Huttrop, Essen

Hungary

2 sites · Ended
Orszagos Onkologiai Intezet
-, Rath Gyorgy Utca 7-9, Kerulet, Budapest XII
Semmelweis Egyetem
Belgyógyászati és Onkológiai Klinika, Baross Utca 23, 1082, Budapest

Italy

8 sites · Ongoing, recruiting
Azienda Unita Sanitaria Locale Della Romagna
Dep. of Oncology, Via Ludwig Van Beethoven 1, 47841, Cattolica
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
U.O. Oncologia, Piazzale Spedali Civili 1, 25123, Brescia
Azienda Ospedaliero Universitaria Parma
Dipartimento di Oncologia Medica, Viale Antonio Gramsci 14, 43126, Parma
Azienda Unita Sanitaria Locale Della Romagna
Dipartimento di Oncologia, Viale Luigi Settembrini 2, 47923, Rimini
Azienda Ospedaliero Universitaria Pisana
U.O. Oncologia, Via Roma 67, 56126, Pisa
European Institute Of Oncology S.r.l.
Dipartimento Divisione di sviluppo di nuovi farmaci per tapie innovative, Via Giuseppe Ripamonti 435, 20141, Milan
IRCCS Istituto Nazionale Tumori Fondazione Pascale
SC Oncologia Clinica Sperimentale di Senologia, Via Mariano Semmola 52, 80131, Naples
Azienda Istituti Ospitalieri Di Cremona
U.O. Patologia Mammaria e Ricerca Traslazionale, Viale Concordia 1, 26100, Cremona

Poland

5 sites · Ended
Med Polonia Sp. z o.o.
Med-Polonia SP.z o.o., Obornicka 262, 60-693, Poznan
Przychodnia Lekarska KOMED Roman Karaszewski
Przychodnia Lekarska KOMED Roman Karaszewski, Wojska Polskiego 6, 62-500, Konin
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Centrum Wsparcia Badań Klinicznyh, Ulica Szaserow 128, 04-141, Warsaw
Instytut Centrum Zdrowia Matki Polki
Klinika Onkologii, Ul. Rzgowska 281/289, 93-338, Lodz
Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.
Pododdział Chemioterapii, Ul. Jana Pawla II 35, 97-200, Tomaszow Mazowiecki

Spain

14 sites · Ongoing, recruiting
Hospital Universitario La Paz
Oncology, Paseo Castellana 261, 28046, Madrid
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Ruber Internacional
Oncology, Calle La Maso 38, 28035, Madrid
Hospital Clinico San Carlos
Oncology, Calle Del Profesor Martin Lagos Sn, 28040, Madrid
Hospital Universitario 12 De Octubre
Oncology, Bloque D, Avenida De Cordoba S/n, Madrid
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitari Vall D Hebron
Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Complexo Hospitalario Universitario A Coruna
Oncology, Lugar Jubias De Arriba 84, 15006, A Coruna
Hospital Clinic De Barcelona
Oncology, Calle Rosellon 138, 08036, Barcelona
Hospital Arnau De Vilanova De Valencia
Oncology, Calle De San Clemente 12, 46015, Valencia
Hospital Beata Maria Ana
Oncology, Calle Del Doctor Esquerdo No. 83, 28007, Madrid
Fundacion Instituto Valenciano De Oncologia
Oncology, Calle De Gregorio Gea 3, Edificio Consultas Externas 1ª Planta, Valencia
Hospital Universitario Virgen De La Victoria
Oncology, Calle Del Arroyo Teatinos S N, 29010, Malaga

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-04-25 2024-05-13
Czechia 2024-01-19
France 2024-04-17 2024-06-10
Germany 2024-06-11
Hungary 2023-12-19
Italy 2024-04-05 2024-05-09
Poland 2024-05-07
Spain 2024-01-30 2024-02-19

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Corrective measures 1 · Art. 77 CTR

Corrective measure CM-FR-0001

Member state
France
Publication date
2024-02-23
Type
3
Reason
7
Immediate action required
Yes
Justification
In line with the version 6.4 of CTR Q&A / point 1.23, the sponsor is requested to submit a specific SM Part II only in France in order to update its CTA in line with the documentation approved during the appeal procedure within 10 days after the submission of this corrective measure.

Application history

13 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-07 Belgium Acceptable with conditions
2023-10-18
2023-10-20
2 SUBSTANTIAL MODIFICATION SM-2 2023-11-29 Belgium Acceptable with conditions
2024-02-09
2024-02-09
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-02-27 Belgium Acceptable with conditions
2024-02-09
2024-02-23
4 SUBSTANTIAL MODIFICATION SM-3 2024-02-28 Acceptable with conditions 2024-03-20
5 NON SUBSTANTIAL MODIFICATION NSM-3 2024-03-27 Belgium Acceptable with conditions 2024-03-27
6 NON SUBSTANTIAL MODIFICATION NSM-4 2024-04-05 Belgium Acceptable with conditions 2024-04-05
7 NON SUBSTANTIAL MODIFICATION NSM-5 2024-06-19 Acceptable with conditions 2024-06-19
8 SUBSTANTIAL MODIFICATION SM-5 2024-07-11 Belgium Acceptable with conditions
2024-10-08
2024-10-08
9 SUBSTANTIAL MODIFICATION SM-7 2024-12-12 Belgium Acceptable with conditions 2025-01-10
10 SUBSTANTIAL MODIFICATION SM-8 2025-08-01 Belgium Acceptable
2025-10-14
2025-10-14
11 NON SUBSTANTIAL MODIFICATION NSM-6 2025-10-30 Acceptable
2025-10-14
2025-10-30
12 SUBSTANTIAL MODIFICATION SM-9 2026-02-11 Acceptable 2026-03-13
13 NON SUBSTANTIAL MODIFICATION NSM-7 2026-03-13 Belgium 2026-03-13